The influence of dialyzer membrane on microcirculation and inflammation in hemodialysis patients.

The influence of dialyzer membrane on microcirculation and inflammation in hemodialysis patients. - The influence of dialyzer membrane on microcirculation and inflammation.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002039

Enrollment

Registered

2009-06-03

Start date

2009-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure

Interventions

Patients of Group 1 will receive EVAL membrane for 12 months. Patients of Group 2 will receive vitamin E-coated PS membrane for 12 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemodialysis patients who used EVAL membrane more than 3 months prior to study initiation.

Exclusion criteria

Exclusion criteria: Patients who did not agree with participating this clinical study.

Design outcomes

Primary

Measure	Time frame
hs-CRP, IL-6, events of hypotension during hemodialysis, SPP and baPWV will be measured at 0, 3, 6, 9 and 12 months after study initiation.	—

Secondary

Measure	Time frame
serum creatinine, serum pre-albumin, serum albumin, muscle volume and BMI will be measured at 0, 3, 6, 9 and 12 months after study initiation.	—

Countries

Japan

Contacts

Public ContactHayato Nishida

Yamagata University, Faculty of Medicine Department of Urology

hnishida331@yahoo.co.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026